AngioDynamics, Inc.
12.12-0.17 (-1.38%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · ANGO · USD
Key Stats
Market Cap
499.34MP/E (TTM)
-Basic EPS (TTM)
-0.78Dividend Yield
0%Recent Filings
8-K
Med Tech surges 26.1%
AngioDynamics kicked off fiscal 2026 with net sales of $75.7 million, up 12.2% pro forma year-over-year, fueled by Med Tech's explosive 26.1% surge to $35.3 million from Auryon, thrombectomy, and NanoKnife platforms. Adjusted EBITDA flipped to $2.2 million from a prior loss, while gross margin climbed to 55.3% amid operational tweaks. Momentum builds. The company raised full-year guidance, targeting $308–$313 million in sales and positive cash flow, yet tariffs could drag $4–$6 million.
10-Q
Q1 FY2026 results
AngioDynamics posted solid Q1 FY2026 results, with net sales climbing 12.2% year-over-year to $75.7 million, fueled by 26.1% growth in the Med Tech segment to $35.3 million from Auryon, NanoKnife, and thrombus management gains, while Med Device edged up 2.3% to $40.5 million amid core and venous strength but port softness. Gross margin expanded 0.9 points to 55.3%, yet operating loss narrowed to $10.7 million from $13.1 million, thanks to lower restructuring costs; net loss improved to $10.9 million, or $0.26 per diluted share on 41.2 million shares. Cash dipped to $38.8 million after $15.9 million operating outflow, but no debt weighs on the $25 million revolver, fully available despite covenants. Restructuring drags on, with $2.3 million in plant closure hits this quarter. Litigation shadows persist, from Bard patent disputes to 219 port product claims.
10-K
FY2025 results
AngioDynamics posted FY2025 revenue of $292.5 million, down 3.8% year-over-year due to divestitures of PICC, midline, dialysis, and BioSentry lines that shaved off $33.4 million, yet Med Tech surged 19.0% to $126.7 million on Auryon growth and stronger thrombus management sales, while Med Device fell 16.0% to $165.8 million from those exits. Gross margins expanded to 53.9%, up 300 basis points, fueled by favorable product mix and volume despite tariff pressures and inflation. Q4 momentum built with Med Tech acceleration, sequential margin gains, and clinical wins like NanoKnife's prostate clearance, though operating loss narrowed to $34.0 million from $184.3 million prior year. Liquidity stayed solid at $55.9 million cash with no debt, bolstered by a $25 million revolver; capital allocation featured $1.7 million in buybacks under a fresh $15 million program. No formal FY2026 guidance issued, but restructuring wraps by Q3 FY2026 to unlock $15 million annual savings. Yet supply chain snarls from tariffs and labor shortages could stall quarterly momentum.
8-K
Strong FY25 results, Med Tech surges
AngioDynamics capped fiscal 2025 with pro forma net sales of $292.7 million, up 8.1% year-over-year, fueled by 19.5% Med Tech growth to $126.7 million while Med Device edged up 0.8% to $166.0 million. The company swung to positive pro forma adjusted EBITDA of $7.6 million from a prior loss, generating $16.2 million in Q4 free cash flow despite $1.6 million tariff hits. Med Tech's momentum accelerates. Fiscal 2026 guidance projects 12-15% Med Tech growth, yet tariffs could shave $4-6 million off EBITDA.
8-K
AngioDynamics secures $25M revolver
AngioDynamics secured a $25 million revolving credit facility from JPMorgan Chase on May 28, 2025, maturing in 2027 and backed by working capital assets. This secured line, announced in April, bolsters liquidity amid manufacturing shifts without tapping existing cash reserves. It carries SOFR plus 2% interest and a 1.05:1 fixed charge coverage covenant post-availability block. Lenders gain first liens on assets; borrowers eye smoother working capital flows.
IPO
Employees
Sector
Industry
AORT
Artivion, Inc.
44.99-0.27
ARAY
Accuray Incorporated
1.44-0.04
ATRC
AtriCure, Inc.
35.44-1.01
BDX
Becton, Dickinson and Company
181.52-2.69
HAE
Haemonetics Corporation
49.44-0.92
LMAT
LeMaitre Vascular, Inc.
88.87-0.67
MBOT
Microbot Medical Inc.
2.13-0.06
MMSI
Merit Medical Systems, Inc.
81.39-1.40
PEN
Penumbra, Inc.
233.37-2.13
SRDX
Surmodics, Inc.
26.93-0.43